Bacteria use a well-studied communication system to resist antibiotics

NewsGuard 100/100 Score

Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system.

P. aeruginosa is responsible for many hospital-acquired infections and also causes chronic infections in those with pre-existing medical conditions such as cystic fibrosis (CF). The bacteria cause persistent lung infections by clumping together to form a biofilm, which spreads over the lungs like a slime. Such biofilms are generally resistant to antibiotics as well as the host immune response.

The study showed that P. aeruginosa uses a well-studied communication system called quorum sensing (QS) to detect approaching white blood cells and warn other bacteria in the biofilm. In response to this signal, the bacteria increase their production of molecules called rhamnolipids. These molecules sit on the biofilm surface to form a shield that destroys any white blood cells that encounter it. Interrupting quorum sensing to halt the "launch a shield" response could be a way of treating these bacteria that can resist antibiotics as well as the host immune system.

Professor Michael Givskov from the University of Copenhagen who led the study believes there are significant clinical benefits to this research. "The ultimate goal [of this research] is to eradicate the present day's antibiotic-resistant bacteria that are involved in the bulk of chronic infections," he says. "Antibiotic resistance is one of the most serious emerging health problems in the world today. More than 70% of the disease-causing bacteria are resistant to at least one of the currently available antibiotics. Studying interactions between P. aeruginosa and the innate and adaptive immune response will provide valuable information for the design of novel antimicrobials".

 

Source: Society for General Microbiology

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gut bacteria manipulation may offer a promising approach to managing inflammatory bowel disease